Recerca

Àrea 3

Oncologia Hepàtica

Factor d'impacte: mitjana: 7.8, total: 382.05

Articles de l'any 2010
Original
  • The use of beta-adrenergic drugs improves hepatic oxygen metabolism in cirrhotic patients undergoing liver resection

    Taura P, Fuster J, Mercadal J, Martinez-Palli G, Fondevila C, Blasi A, Balust J, Garcia-Valdecasas JC
    J HEPATOL. 2010; 52: 340-347. IF: 7.818

  • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage

    Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Sole M, Thung S, Moyano S, Toffanin S, Minguez B, Cabellos L, Peix J, Schwartz M, Mazzaferro V, Bruix J, Llovet JM
    J HEPATOL. 2010; 52: 550-559. IF: 7.818

  • Portal Hyperperfusion: Mechanism of Injury and Stimulus for Regeneration in Porcine Small-for-Size Transplantation

    Fondevila C, Hessheimer AJ, Taura P, Sanchez O, Calatayud D, DeRiva N, Munoz J, Fuster J, Rimola A, Garcia-Valdecasas JC
    LIVER TRANSPLANT. 2010; 16: 364-374. IF: 3.724

  • Combined liver-kidney transplantation in patients with cirrhosis and chronic kidney disease

    Baccaro ME, Pepin MN, Guevara M, Colmenero J, Torregrosa JV, Martin-Llahi M, Sola E, Esforzado N, Fuster J, Campistol JM, Arroyo V, Navasa M, Garcia-Valdecasas J, Gines P
    NEPHROL DIAL TRANSPL. 2010; 25: 2356-2363. IF: 3.306

  • A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

    Greten TF, Forner A, Korangy F, N'kontchou G, Barget N, Ayuso C, Ormandy LA, Manns MP, Beaugrand M, Bruix J
    BMC CANCER. 2010; 10: 0-0. IF: 2.736

  • A Meta-Analysis of Survival Rates of Untreated Patients in Randomized Clinical Trials of Hepatocellular Carcinoma

    Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C
    HEPATOLOGY. 2010; 51: 1274-1283. IF: 10.84

  • Acute Portal Vein Thrombosis Unrelated to Cirrhosis: A Prospective Multicenter Follow-up Study

    Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, Heller J, Morard I, Lasser L, Langlet P, Denninger MH, Vidaud D, Condat B, Hadengue A, Primignani M, Garcia-Pagan JC, Janssen HLA, Valla D
    HEPATOLOGY. 2010; 51: 210-218. IF: 10.84

  • Intrahepatic Peripheral Cholangiocarcinoma in Cirrhosis Patients May Display a Vascular Pattern Similar to Hepatocellular Carcinoma on Contrast-Enhanced Ultrasound

    Vilana R, Forner A, Bianchi L, Garcia-Criado A, Rimola J, DeLope CR, Reig M, Ayuso C, Bru C, Bruix J
    HEPATOLOGY. 2010; 51: 2020-2029. IF: 10.84

  • Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma

    Hessheimer AJ, Forner A, Varela M, Bruix J
    EUR J GASTROEN HEPAT. 2010; 22: 1239-1244. IF: 1.662

  • Serum neutrophil gelatinase-associated lipocalin in patients with colorectal liver metastases: preliminary results of an exploratory prospective study

    Marti J, Fuster J, Hotter G, Sola AM, Deulofeu R, Modolo MM, Loera MA, Ferrer J, Fondevila C, Garcia-Valdecasas JC
    INT J BIOL MARKER. 2010; 25: 21-26. IF: 1.419

  • Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers

    Varela M, Reig M, DeLaMata M, Matilla A, Bustamante J, Pascual S, Turnes J, Aracil C, DelVal A, Pascasio JM, Rodriguez M, Bruix J
    MED CLIN-BARCELONA . 2010; 134: 569-576. IF: 1.231

Revisió
  • Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy

    Villanueva A, Minguez B, Forner A, Reig M, Llovet JM
    ANNU REV MED. 2010; 61: 317-328. IF: 9.94

  • Cancer gene discovery in hepatocellular carcinoma

    Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM
    J HEPATOL. 2010; 52: 921-929. IF: 7.818

  • New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers

    Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, Llovet JM
    CLIN CANCER RES. 2010; 16: 4688-4694. IF: 6.747

  • Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements

    Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM
    SEMIN LIVER DIS. 2010; 30: 35-51. IF: 5.171

  • Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

    Lencioni R, Llovet JM
    SEMIN LIVER DIS. 2010; 30: 52-60. IF: 5.171

  • Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects

    Forner A, Reig ME, DeLope CR, Bruix J
    SEMIN LIVER DIS. 2010; 30: 61-74. IF: 5.171

Editorials
  • Ablation for hepatocellular carcinoma: Is there need to have a winning technique?

    Forner A, Bruix J
    J HEPATOL. 2010; 52: 310-312. IF: 7.818

  • Treating hepatitis C in patients with cirrhosis: The effort is worth it

    Forns X, Bruix J
    J HEPATOL. 2010; 52: 624-626. IF: 7.818

  • Two Decades of Advances in Hepatocellular Carcinoma Research FOREWORD

    Bruix J, Llovet JM
    SEMIN LIVER DIS. 2010; 30: 1-2. IF: 5.171

  • Obesity, Inflammatory Signaling, and Hepatocellular Carcinoma-An Enlarging Link

    Toffanin S, Friedman SL, Llovet JM
    CANCER CELL. 2010; 17: 115-117. IF: 25.288

  • miRNA delivery: emerging therapy for hepatocellular carcinoma

    Toffanin S, Villanueva A, Llovet JM
    GASTROENTEROLOGY. 2010; 138: 1202-1204. IF: 12.899

  • Hippo tumor supressor pathway: novel implications for the treatment of hepatocellular carcinoma

    Lachenmayer A, Hoshida Y, Llovet JM
    GASTROENTEROLOGY. 2010; 139: 692-694. IF: 12.899

  • MicroRNA analysis for outcome prediction in hepatitis B virus-related liver cancer

    Boix L, Bruix J
    GASTROENTEROLOGY. 2010; 138: 1624-1626. IF: 12.899

  • Failure of interferon to prevent disease progression and liver cancer in hepatitis C virus infection: proof of absence or absence of proof?

    DeLope CR, Bruix J
    GASTROENTEROLOGY. 2010; 138: 777-779. IF: 12.899

  • Multifaceted Perspective of the Waiting List for Liver Transplantation: The Value of Pharmacokinetic Models

    Navasa M, Bruix J
    HEPATOLOGY. 2010; 51: 12-15. IF: 10.84

Multicèntrics
  • Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer A Meta-analysis

    Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, VanCutsem E, Buyse M
    JAMA-J AM MED ASSOC. 2010; 303: 1729-1737. IF: 28.899

Guies clíniques
  • Hepatocellular Carcinoma (HCC) A Global Perspective

    Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, Zheng SS, Sarin S, Hamid SS, Modawi SB, Fleig W, Fedail S, Thomson A, Khan A, Malfertheiner P, Lau G, Carillo FJ, Krabshuis J, LeMair A
    J CLIN GASTROENTEROL. 2010; 44: 239-245. IF: 2.207

Tornar